Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18–60 years: A double-blind, non-inferiority, randomized controlled trial

This publication has 15 references indexed in Scilit:

• COVID-19 infection and ginseng: Predictive influenza virus strains and non-predictive COVID-19 vaccine strains
  Journal of Ginseng Research, 2022
• Systematic review of the efficacy, effectiveness and safety of cell‐based seasonal influenza vaccines for the prevention of laboratory‐confirmed influenza in individuals ≥18 years of age
  Reviews in Medical Virology, 2022
• Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis
  Journal of Infection, 2022
• Influenza’s Unprecedented Low Profile During COVID-19 Pandemic Leaves Experts Wondering What This Flu Season Has in Store
  JAMA, 2021
• Economic burden of seasonal influenza in the United States
  Vaccine, 2018
• Efficacy of Recombinant Influenza Vaccine in Adults 50 Years of Age or Older
  New England Journal of Medicine, 2017
• Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials
  Vaccine, 2016
• Randomized comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age
  Vaccine, 2015
• Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: A systematic review with meta-analyses of controlled trials
  Vaccine, 2012
• FluBlok, a recombinant hemagglutinin influenza vaccine
  Influenza and Other Respiratory Viruses, 2008